Citations

Showing 10 of 108083 citations.

Local Recurrence Rates of Malignant Melanoma After Mohs Micrographic Surgery Are Lowest With 5- to 10-mm Initial Margins: A Systematic Review and Meta-Analysis
Campbell, Elliott H. , Crum, Olivia M. , Chelf, Cynthia , Demer, Addison M. , Brewer, Jerry D., Chelf, Cynthia J, Chelf, Cynthia J

Mayo Clinic

Dermatologic Surgery | February 2, 2023 | Volume: 49 | Issue: 2 | Pages: 119-123

10.1097/dss.0000000000003683 | PMID 36728060 Get It

BACKGROUND Current consensus guidelines have discouraged the use of sub-0.5-cm (in situ) and sub-1-cm (invasive) margins when performing Mohs micrographic surgery (Mohs) for melanoma, with minimal evidence to guide this recommendation. OBJECTIVE To compare melanoma local recurrence rates after Mohs based on initial margin size. MATERIALS AND METHODS A systematic review and meta-analysis was conducted with search terms including Mohs micrographic surgery, surgical margin, recurrent disease, and melanoma. RESULTS Forty-three studies were included. The 5- to 10-mm margin category had a statistically significant lower local recurrence compared with 1- to 5-mm and 5-mm categories. Recurrence for 1- to 5-mm, 5-mm, 5- to 10-mm, and 10-mm categories were 2.3% (CI 0.8–3.5, p < .001), 1.4% (CI 0.6–2.2, p < .001), 0.3% (CI 0.2–0.5, p < .001), and 6.1% (CI -6.7 - 18.8, p = .349), respectively. Number of stages for 1 to 5, 5, 5 to 10, and 10-mm categories were 1.8, 1.8, 1.6, and 1.6, respectively. There was no statistically significant difference between the groups (p = .694). CONCLUSION Five- to 10-mm margins were associated with the lowest local recurrence rates. A 5- to 10-mm initial margin should be considered where other factors (tumor characteristics, anatomical or functional considerations) allow.
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Rinella, Mary E. , Neuschwander‐Tetri, Brent A. , Siddiqui, Mohammad Shadab , Abdelmalek, Manal F. , Caldwell, Stephen H. , Barb, Diana , Kleiner, David E. , Caldwell, Stephen , Loomba, Rohit , Kleiner, David Erwin , Rinella, Mary , Neuschwander-Tetri, Brent , Abdelmalek, Manal , Loomba, Rohit

Mayo Clinic

Hepatology | February 2, 2023 | Volume: 77 | Issue: 5 | Pages: 1797-1835

10.1097/hep.0000000000000323 | PMID 36727674 Get It

Molecular evolution in different subtypes of multifocal hepatocellular carcinoma
Ding, Keyue , Tang, Xia , Li, Qingshu , Shao, Yue, Wan, Li , Zhao, Dachun, Li, Xiaoyuan , Wu, Songfeng , Wang, Haijian , Xiang, Lei, Li, Dewei

Mayo Clinic

No container title available | February 2, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2515298/v1 Get It

Abstract Background: Multifocal hepatocellular carcinoma (MF-HCC) accounts for >40% of HCCs, demonstrating a poor prognosis than single primary HCCs. Characterizing the dynamic changes of mutation signature along with clonal evolution, quantifying intrahepatic metastatic timing, and investigating the genetic structure in the preneoplastic stage underlying different subtypes of MF-HCC are important for understanding their molecular evolution and developing a precision management strategy. Methods: We conducted whole-exome sequencing in 74 tumor samples from spatially distinct regions in 35 resected tumor lesions and adjacent non-cancerous tissues in 11 patients with synchronous MF-HCCs, 15 histologically confirmed preneoplastic lesions and six samples from peripheral blood mononuclear cell. We also used the previously published MF-HCC cohorts (n=9) as an independent validation dataset. Results: We classified MF-HCCs into three subtypes, including intrahepatic metastasis, multicentric occurrence, and mixed intrahepatic metastasis and multicentric occurrence. The dynamic changes in mutation signatures between tumor subclonal expansions demonstrated varied etiologies underlying the clonal progression in different MF-HCC subtypes, especially the contribution of aristolochic acid exposure decreased along with subclonal expansions. The clonal evolution in intrahepatic metastasis exhibited an early metastatic seeding that occurred at 10-4–0.01 cm3 in primary tumor volume, below the limitation in clinical detection. These findings were validated in another independent cohort. In addition, for multicentric occurrence MF-HCC, mutational footprints in the preneoplastic lesions revealed common preneoplastic arising clones, evidently being ancestors of different tumor sites. Conclusion: Our study comprehensively characterized the dynamic mutational signature, early metastatic timing, and common preneoplastic clones in multicentric occurrence that characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC, and provided important implications for optimizing personalized clinical management for MF-HCC.
Acuity circles allocation policy impact on waitlist mortality and donation after circulatory death liver transplantation: A nationwide retrospective analysis
Giorgakis, Emmanouil , Wallace, David , Wells, Allison, Balogh, Julius , Hardgrave, Hailey , Krinock, Derek , Burdine, Lyle , Singer, Andrew L., Mathur, Amit K. , Balogh, Julius , Singer, Andrew, Giorgakis, Emmanouil , Ivanics, Tommy , Klutts, Garrett N.

Mayo Clinic

Health Science Reports | February 2, 2023 | Volume: 6 | Issue: 2 | Pages: No page available

10.1002/hsr2.1066 | PMID 36751274 Get It

One-Stage Synovectomies Result in Improved Short-Term Outcomes Compared to Two-Stage Synovectomies of Diffuse-Type Tenosynovial Giant Cell Tumor (D-TGCT) of the Knee: A Multicenter, Retrospective, Cohort Study
Spierenburg, Geert , Verspoor, F.G.M. , Wunder, Jay S. , Griffin, Anthony M. , Houdek, Matthew T. , King, David M. , Boyle, Richard , Randall, R. Lor , Thorpe, Steven W. , Priester, Jacob , Geiger, Erik J. , Schreuder, Bart, Gelderblom, Hans , Sande, Michiel A. J. van de , Houdek, Matthew T , Randall, Robert Lor , Gelderblom, Hans , van de Sande, Michiel A J , Ferguson, Peter C. , Boyle, Richard, Heijden, Lizz van der , Bernthal, Nicholas M

Mayo Clinic

Cancers | February 2, 2023 | Volume: 15 | Issue: 3 | Pages: 941

10.3390/cancers15030941 | PMID 36765897 Get It

Diffuse-type tenosynovial giant cell tumors’ (D-TGCTs) intra- and extra-articular expansion about the knee often necessitates an anterior and posterior surgical approach to facilitate an extensive synovectomy. There is no consensus on whether two-sided synovectomies should be performed in one or two stages. This retrospective study included 191 D-TGCT patients from nine sarcoma centers worldwide to compare the postoperative short-term outcomes between both treatments. Secondary outcomes were rates of radiological progression and subsequent treatments. Between 2000 and 2020, 117 patients underwent one-stage and 74 patients underwent two-stage synovectomies. The maximum range of motion achieved within one year postoperatively was similar (flexion 123–120°, p = 0.109; extension 0°, p = 0.093). Patients undergoing two-stage synovectomies stayed longer in the hospital (6 vs. 4 days, p < 0.0001). Complications occurred more often after two-stage synovectomies, although this was not statistically different (36% vs. 24%, p = 0.095). Patients treated with two-stage synovectomies exhibited more radiological progression and required subsequent treatments more often than patients treated with one-stage synovectomies (52% vs. 37%, p = 0.036) (54% vs. 34%, p = 0.007). In conclusion, D-TGCT of the knee requiring two-side synovectomies should be treated by one-stage synovectomies if feasible, since patients achieve a similar range of motion, do not have more complications, but stay for a shorter time in the hospital.
The Use of Ultrasonic Bone Scalpel (UBS) in Unilateral Biportal Endoscopic Spine Surgery (UBESS): Technical Notes and Outcomes
Tsai, Sung Huang Laurent , Lin, Tung‐Yi , Wang, Ying-Chih , Wong, Chak-Bor, Ghaith, Abdul Karim , Fu, Tsai‐Sheng , Bydon, Mohamad , Lin, Tung-Yi , Wang, Ying-Chih , Ghaith, Abdul Karim , Chang, Chia-Wei , Alvi, Mohammed Ali

Mayo Clinic

Journal of Clinical Medicine | February 2, 2023 | Volume: 12 | Issue: 3 | Pages: 1180

10.3390/jcm12031180 | PMID 36769829 Get It

Study Design: Case Series and Technical Note, Objective: UBS has been extensively used in open surgery. However, the use of UBS during UBESS has not been reported in the literature. The aim of this study was to describe a new spinal surgical technique using an ultrasonic bone scalpel (UBS) during unilateral biportal endoscopic spine surgery (UBESS) and to report the preliminary results of this technique. Methods: We enrolled patients diagnosed with lumbar spinal stenosis who underwent single-level UBESS. All patients were followed up for more than 12 months. A unilateral laminotomy was performed after bilateral decompression under endoscopy. We used the UBS system after direct visualization of the target for a bone cut. We evaluated the demographic characteristics, diagnosis, operative time, and estimated blood loss of the patients. Clinical outcomes included the visual analog scale (VAS), the Oswestry Disability Index (ODI), the modified MacNab criteria, and postoperative complications. Results: A total of twenty patients (five males and fifteen females) were enrolled in this study. The mean follow-up period was 13.2 months (range 12–17 months). The VAS score, ODI, and modified MacNab criteria classification improved after the surgery. A minimal mean blood loss of 22.1 mL was noted during the operation. Only one patient experienced neuropraxia, which resolved within 2 weeks. There was no durotomy, iatrogenic pars fracture, or infection. Conclusions: In conclusion, our study represents the first report of the use of UBS during UBESS. Our findings demonstrate that this technique is safe and efficient, with improved clinical outcomes and minimal complications. These preliminary results warrant further investigation through larger clinical studies with longer follow-up periods to confirm the effectiveness of this technique in the treatment of lumbar spinal stenosis.
Commentary on A Patient with Third-Space Fluid Loss
Block, Darci R

Mayo Clinic

Clinical Chemistry | February 2, 2023 | Volume: 69 | Issue: 2 | Pages: 128-129

10.1093/clinchem/hvac206 | PMID 36724484 Get It

Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies
Castillo, Jorge J. , Castillo, Jorge J , Muñoz, Javier , Sarosiek, Shayna

Mayo Clinic

The Oncologist | February 2, 2023 | Volume: 28 | Issue: 4 | Pages: 309-318

10.1093/oncolo/oyac260 | PMID 36723874 Get It

AbstractIbrutinib is a first-generation inhibitor of Bruton tyrosine kinase (BTK) that is currently approved to treat patients with B-cell malignancies, including Waldenström macroglobulinemia (WM), relapsed/refractory (R/R) mantle cell lymphoma (MCL), R/R marginal zone lymphoma (MZL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Off-target adverse effects, such as atrial fibrillation, hypertension, and bleeding, have been observed and may limit a patient’s tolerance for treatment. Currently, there is no well-established treatment regimen for patients who cannot tolerate ibrutinib. Approaches to address such patients include managing ibrutinib side effects with supportive care or dose reductions, switching to an alternative covalent BTK inhibitor, or abandoning covalent BTK inhibitors for alternative forms of treatment. Here we review the literature and provide guidance on treating ibrutinib-intolerant patients with B-cell malignancies.
Potential risks of non-cardiac peri-operative myocardial infarction/injury
Thygesen, Kristian , Jaffe, Allan S. , Jaffe, Allan S.

Mayo Clinic

European Heart Journal | February 2, 2023 | Volume: 44 | Issue: 19 | Pages: 1702-1704

10.1093/eurheartj/ehac768 | PMID 36723987 Get It

Brain glucose metabolism and nigrostriatal degeneration in isolated rapid eye movement sleep behaviour disorder
Diaz‐Galvan, Patricia , Miyagawa, Toji , Przybelski, Scott A. , Lesnick, Timothy G. , Jack, Clifford R. , Forsberg, Leah K. , Min, Hoon‐Ki , Louis, Erik K. St. , Savica, Rodolfo , Fields, Julie A. , Benarroch, Eduardo E. , Lowe, Val J. , Petersen, Ronald C. , Boeve, Bradley F. , Kantarci, Kejal , Jack, Clifford R , St Louis, E K , Boeve, Brad , Kantarci, Kejal , Min, Hoon-Ki Paul , Diaz-Galvan, Patricia , Senjem, Matthew L.

Mayo Clinic

Brain Communications | February 1, 2023 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcad021 | PMID 36844148 Get It

AbstractAlterations of cerebral glucose metabolism can be detected in patients with isolated rapid eye movement sleep behaviour disorder, a prodromal feature of neurodegenerative diseases with α-synuclein pathology. However, metabolic characteristics that determine clinical progression in isolated rapid eye movement sleep behaviour disorder and their association with other biomarkers need to be elucidated. We investigated the pattern of cerebral glucose metabolism on 18F-fluorodeoxyglucose PET in patients with isolated rapid eye movement sleep behaviour disorder, differentiating between those who clinically progressed and those who remained stable over time. Second, we studied the association between 18F-fluorodeoxyglucose PET and lower dopamine transporter availability in the putamen, another hallmark of synucleinopathies. Patients with isolated rapid eye movement sleep behaviour disorder from the Mayo Clinic Alzheimer’s Disease Research Center and Center for Sleep Medicine (n = 22) and age-and sex-matched clinically unimpaired controls (clinically unimpaired; n = 44) from the Mayo Clinic Study of Aging were included. All participants underwent 18F-fluorodeoxyglucose PET and dopamine transporter imaging with iodine 123-radiolabeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane on single-photon emission computerized tomography. A subset of patients with isolated rapid eye movement sleep behaviour disorder with follow-up evaluations (n = 17) was classified as isolated rapid eye movement sleep behaviour disorder progressors (n = 7) if they developed mild cognitive impairment or Parkinson’s disease; or isolated rapid eye movement sleep behaviour disorder stables (n = 10) if they remained with a diagnosis of isolated rapid eye movement sleep behaviour disorder with no cognitive impairment. Glucose metabolic abnormalities in isolated rapid eye movement sleep behaviour disorder were determined by comparing atlas-based regional 18F-fluorodeoxyglucose PET uptake between isolated rapid eye movement sleep behaviour disorder and clinically unimpaired. Associations between 18F-fluorodeoxyglucose PET and dopamine transporter availability in the putamen were analyzed with Pearson’s correlation within the nigrostriatal pathway structures and with voxel-based analysis in the cortex. Patients with isolated rapid eye movement sleep behaviour disorder had lower glucose metabolism in the substantia nigra, retrosplenial cortex, angular cortex, and thalamus, and higher metabolism in the amygdala and entorhinal cortex compared with clinically unimpaired. Patients with isolated rapid eye movement sleep behaviour disorder who clinically progressed over time were characterized by higher glucose metabolism in the amygdala and entorhinal cortex, and lower glucose metabolism in the cerebellum compared with clinically unimpaired. Lower dopamine transporter availability in the putamen was associated with higher glucose metabolism in the pallidum within the nigrostriatal pathway; and with higher 18F-fluorodeoxyglucose uptake in the amygdala, insula, and temporal pole on a voxel-based analysis, although these associations did not survive after correcting for multiple comparisons. Our findings suggest that cerebral glucose metabolism in isolated rapid eye movement sleep behaviour disorder is characterized by hypometabolism in regions frequently affected during the prodromal stage of synucleinopathies, potentially reflecting synaptic dysfunction. Hypermetabolism is also seen in isolated rapid eye movement sleep behaviour disorder, suggesting that synaptic metabolic disruptions may be leading to a lack of inhibition, compensatory mechanisms, or microglial activation, especially in regions associated with nigrostriatal degeneration.